ChromaDex Corporation (CDXC) Stock Analysis

ChromaDex Corporation (CDXC) Healthcare & Pipeline Overview

ChromaDex Corporation is a bioscience company focused on healthy aging, developing and commercializing nicotinamide adenine dinucleotide (NAD+) precursors. The company's flagship ingredient, NIAGEN, is sold directly to consumers through its e-commerce platform and to manufacturers for use in their products, positioning ChromaDex in the growing market for healthy aging solutions.

What Is the Investment Thesis for CDXC?

ChromaDex Corporation presents a notable research candidate within the growing healthy aging market. The company's focus on NAD+ precursors, particularly its flagship ingredient NIAGEN, positions it to capitalize on increasing consumer awareness of the importance of cellular health. With a gross margin of 64.3% and a profit margin of 14.3%, ChromaDex demonstrates strong profitability. Key growth catalysts include expanding distribution channels for TRU NIAGEN and increasing sales of NIAGEN to manufacturers. However, the company's high beta of 2.21 indicates significant volatility. The company's P/E ratio is 17.88. ChromaDex's success hinges on continued scientific validation of NIAGEN's benefits and effective marketing to drive consumer demand.

Based on FMP financials and quantitative analysis

CDXC Key Highlights

Market Cap of $612M reflects ChromaDex's current valuation in the bioscience sector.

• P/E Ratio of 17.88 indicates the price investors are willing to pay for each dollar of ChromaDex's earnings.
• Profit Margin of 14.3% demonstrates ChromaDex's ability to generate profit from its revenue.
• Gross Margin of 64.3% showcases the efficiency of ChromaDex's production and pricing strategies.
• Beta of 2.21 suggests that ChromaDex's stock is more volatile than the overall market.

Who Are CDXC's Competitors?

CDXC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDXC's Key Strengths?

Proprietary and patented NIAGEN ingredient.

• Strong brand recognition with TRU NIAGEN.
• Direct-to-consumer sales channel through TRUNIAGEN.com.
• Established relationships with manufacturers and distributors.

What Are CDXC's Weaknesses?

Reliance on a single key ingredient (NIAGEN).

• High beta indicates significant stock volatility.
• Limited product diversification.
• Dependence on third-party manufacturers for some products.

What Could Drive CDXC Stock Higher?

Continued expansion of TRU NIAGEN distribution channels.

• Increasing sales of NIAGEN to manufacturers.
• Potential positive results from ongoing clinical trials on NIAGEN.
• Launch of new NAD+ boosting products.
• Strategic acquisitions and partnerships.

What Are the Key Risks for CDXC?

Competition from other companies in the healthy aging market.

• Adverse regulatory changes affecting the dietary supplement industry.
• Patent infringement or challenges to NIAGEN patent.
• Fluctuations in raw material costs.
• High beta indicates significant stock volatility.

What Are the Growth Opportunities for CDXC?

• Expansion of TRU NIAGEN Distribution Channels: ChromaDex can significantly increase its revenue by expanding its distribution channels for TRU NIAGEN. This includes partnerships with major retailers, pharmacies, and international distributors. The global dietary supplements market is projected to reach $230.73 billion by 2027, providing a large market for TRU NIAGEN. Timeline: Ongoing, with continuous efforts to secure new distribution agreements.
• Increased Sales of NIAGEN to Manufacturers: ChromaDex can drive growth by increasing sales of NIAGEN as a raw material to manufacturers of consumer products. This includes companies in the dietary supplement, food and beverage, and cosmetic industries. Timeline: Ongoing, with targeted marketing and sales efforts to key manufacturers.
• Development of New NAD+ Boosting Products: ChromaDex can expand its product portfolio by developing new NAD+ boosting products targeting specific health concerns, such as cognitive function, cardiovascular health, and muscle recovery. Timeline: 2-3 years, with ongoing research and development efforts.
• Strategic Acquisitions and Partnerships: ChromaDex can accelerate its growth through strategic acquisitions and partnerships with companies in the healthy aging and biotechnology sectors. This includes acquiring complementary technologies, expanding its product portfolio, and gaining access to new markets. Timeline: Ongoing, with active evaluation of potential acquisition targets.
• Increased Focus on International Markets: ChromaDex can tap into significant growth opportunities by expanding its presence in international markets, particularly in Asia and Europe, where there is growing demand for healthy aging products. The Asia-Pacific dietary supplements market is expected to grow rapidly in the coming years. Timeline: 1-2 years, with targeted market entry strategies and partnerships.

What Are CDXC's Competitive Advantages?

• Patented NIAGEN ingredient provides a competitive advantage.
• Strong brand recognition and reputation in the healthy aging market.
• Proprietary e-commerce platform for direct-to-consumer sales.
• Established relationships with manufacturers and distributors.

What Does CDXC Do?

ChromaDex Corporation, headquartered in Los Angeles, California, was founded with a focus on researching and developing innovative ingredients for the healthy aging market. The company operates through three segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. ChromaDex's core research centers around nicotinamide adenine dinucleotide (NAD+), a critical coenzyme found in every cell in the body. The company's flagship ingredient, NIAGEN (nicotinamide riboside), is a patented form of vitamin B3 and a precursor to NAD+. ChromaDex commercializes NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN brand and supplies it as a raw material to manufacturers of consumer products. TRU NIAGEN products are distributed directly to consumers through the company's e-commerce platform, TRUNIAGEN.com, Amazon, and other internet marketplaces. The company also distributes through specialty retailers and direct healthcare practitioners in the United States. In addition to NIAGEN, ChromaDex offers IMMULINA, a Braun-type lipoprotein derived from spirulina extracts, which supports human immune function. ChromaDex also provides analytical reference standards and services, offering products for quality control of raw materials and consumer products across various industries, including dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. ChromaDex's commitment to scientific research and innovation has positioned it as a key player in the healthy aging market.

What Products and Services Does CDXC Offer?

• Researches nicotinamide adenine dinucleotide (NAD+) and its role in healthy aging.
• Develops and commercializes proprietary-based ingredient technologies.
• Supplies NIAGEN as a raw material to manufacturers of consumer products.
• Offers analytical reference standards and services for quality control.
• Sells TRU NIAGEN products directly to consumers through its e-commerce platform.
• Distributes TRU NIAGEN through Amazon, other internet marketplaces, specialty retailers, and healthcare practitioners.

How Does CDXC Make Money?

• Sells finished dietary supplement products containing NIAGEN directly to consumers.
• Supplies NIAGEN as a raw material to manufacturers of consumer products.
• Provides analytical reference standards and services for quality control.
• Generates revenue through its e-commerce platform TRUNIAGEN.com and other online marketplaces.

What Industry Does CDXC Operate In?

ChromaDex operates in the rapidly expanding biotechnology industry, specifically targeting the healthy aging market. This market is driven by increasing consumer interest in longevity and preventative health measures. The competitive landscape includes companies developing and marketing similar NAD+ boosting supplements and other anti-aging products. ChromaDex differentiates itself through its patented NIAGEN ingredient and its focus on scientific validation.

Who Are CDXC's Key Customers?

• Individual consumers seeking healthy aging solutions.
• Manufacturers of dietary supplements, food and beverages, and cosmetics.
• Researchers and scientists in the life sciences and pharmaceutical industries.
• Quality control laboratories in various industries.

Company Profile

ChromaDex Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Frank Louis Jaksch Jr.. CDXC has traded publicly since 2008.

ChromaDex Corporation's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 14.59 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for ChromaDex Corporation stands at 25.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.3%, showing how much profit it generates from its asset base. CDXC trades at a trailing price-to-earnings ratio of 13.68, below the Healthcare sector average of ~23x. Its free cash flow yield is 1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.3%, the inverse of the P/E and a quick read on earnings relative to price.

CDXC Valuation & Market Position

With a $612M market cap, ChromaDex Corporation sits in the small-cap segment of the market.

Wall Street analysts project ChromaDex Corporation revenue of about $143.8M for fiscal 2026, with EPS near $0.20. The estimate reflects 4 contributing analysts.

CDXC Financials

CDXC Latest News

No recent news available for CDXC.

CDXC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources